Benzinga | Oct 11, 2021 10:31AM EDT

UPDATE: Nymox Pharmaceutical CEO Says 'main delayed vendor documentation that was incomplete has been accomplished'

Company CEO Paul Averback stated, "We are happy to follow-up today and tell our shareholders that the main delayed vendor documentation that was incomplete has been accomplished. We are now certain to have our full documentation for those materials completed. There remain some standard quality control steps that are typically involved. Our next follow-up is expected to provide a more exact forward date for filing as soon as it is in our hands very soon in this quarter. We emphasize again that it is fully in the best interests of our shareholders that management concerns itself with required quality regulations and stays focused on doing things properly, regardless of the recent very minor adjustments to the timeline, which are beyond our control."

The Company also announced today that it will be participating in several investor conferences and meetings in the upcoming months.